Recruiting Alzheimers Disease Studies in Fairway
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants ag...
A Study of IBI363 in Subjects with Advanced Solid Malignancies
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies....
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of co...
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with...
About Alzheimers Disease Clinical Trials in Fairway
Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.
There are currently 4 alzheimers disease clinical trials recruiting participants in Fairway, KANSAS. These studies are seeking a combined 749 participants. Research is being sponsored by Sanofi, Innovent Biologics (Suzhou) Co. Ltd., Novita Pharmaceuticals, Inc. and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Alzheimers Disease Clinical Trials in Fairway — FAQ
Are there alzheimers disease clinical trials in Fairway?
Yes, there are 4 alzheimers disease clinical trials currently recruiting in Fairway, KANSAS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Fairway?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fairway research site will contact you about next steps.
Are clinical trials in Fairway free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fairway studies also compensate for your time and travel.
What alzheimers disease treatments are being tested?
The 4 active trials in Fairway are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.
Data updated March 2, 2026 from ClinicalTrials.gov